API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Ezharmia (valemetostat tosilate) is a first-in-class dual inhibitor of EZH1 and EZH2. It is being evaluated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: Ezharmia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Ezharmia (valemetostat tosylate) is a USFDA approved first-in-class dual inhibitor of EZH1 and EZH2. It is under phase 2 clinical development for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: Ezharmia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2023
Details:
Ezharmia (valemetostat tosilate) is a first-in-class dual inhibitor of EZH1 and EZH2 currently in clinical development for the treatment of several types of non-Hodgkin lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: Ezharmia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
EZHARMIA (valemetostat tosilate) is a first-in-class dual inhibitor of EZH1 and EZH2 currently in clinical development for treatment of several types of non-Hodgkin lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: Ezharmia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2 currently in clinical development in the Alpha portfolio of Daiichi Sankyo. The valemetostat development program includes a global pivotal phase 2 trial in patients with relapsed/refractory PTCL and ATL.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2021
Details:
DS-3201 (valemetostat), a potential first-in-class dual inhibitor of EZH1 and EZH2, demonstrated promising response rates in a pivotal phase 2 study in Japanese patients with relapsed/refractory adult T-cell.leukemia/lymphoma (ATL).
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2021
Details:
Oral presentation highlights data from phase 1 study of valemetostat showing promising clinical activity in patients with relapsed/refractory PTCL and ATL. DS-3201 is a potential first-in-class, potent and selective small molecule EZH1/2 dual inhibitor.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Valemetostat (DS-3201) is a potential first-in-class, potent and selective small molecule EZH1/2 dual inhibitor currently in clinical development in the Alpha portfolio of Daiichi Sankyo.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
The partnership brings together Daiichi Sankyo, the Lymphoma Academic Research Organization, and the CALYM research alliance to perform clinical and translational research on valemetostat in patients with relapsed/refractory non-Hodgkin lymphoma.
Lead Product(s): Valemetostat
Therapeutic Area: Oncology Product Name: DS-3201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 24, 2021